Subtype
Bladder Carcinoma
CI-CAN-00007316Explore in graph →
141 active trials7 approved drugs19 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00007316Explore in graph →
Clinical trials
332 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (49)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07505615 | A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer(VG-INFUSE Tria) | completed | Phase 1 / Phase 2 | 20 | Ding-Wei YeOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT01616875 | Bristol Bladder Trial | completed | Phase 2 | 28 | University Hospitals Bristol and Weston NHS Foundation TrustOTHER | 1 | Mar 6, 2026 |
| clinicaltrials |
| NCT03914794 | A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT04383743 | Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer | completed | Phase 2 | 17 | University of WashingtonOTHER | 1 | Sep 18, 2025 | clinicaltrials |
| NCT04570410 | Primary Excision Combined With Preoperative Neoadjuvant and Adjuvant Therapy for Oligometastasis of Urothelial Carcinoma | completed | Phase 2 | 30 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 5, 2025 | clinicaltrials |
| NCT02844816 | Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer | completed | Phase 2 | 172 | National Cancer Institute (NCI)NIH | 2 | May 22, 2025 | clinicaltrials |
| NCT02567409 | Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 | clinicaltrials |
| NCT04496219 | Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer | completed | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT03421652 | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT03617913 | Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer | completed | Phase 2 | 2 | Mayo ClinicOTHER | 1 | Jan 6, 2023 | clinicaltrials |
| NCT00238420 | Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer | completed | Phase 1 / Phase 2 | 70 | National Cancer Institute (NCI)NIH | 2 | Jul 19, 2022 | clinicaltrials |
| NCT03430895 | Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract | completed | Phase 2 | 15 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT00118040 | Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Jun 10, 2021 | clinicaltrials |
| NCT02009332 | Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | Aadi Bioscience, Inc.INDUSTRY | 1 | Jun 8, 2021 | clinicaltrials |
| NCT00749892 | Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer | completed | Phase 2 | 34 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 10, 2020 | clinicaltrials |
| NCT03672240 | Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment(NMIBC) | completed | Phase 1 / Phase 2 | 6 | Asieris Pharmaceutical Technologies Co., Ltd.INDUSTRY | 1 | Jul 20, 2020 | clinicaltrials |
| NCT02178241 | Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery | completed | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 2 | Dec 16, 2019 | clinicaltrials |
| NCT02355886 | Gabapentin in Reducing the Need for Pain Medication in Patients With Bladder Cancer Undergoing Radical Cystectomy | completed | Phase 2 / Phase 3 | 25 | University of WashingtonOTHER | 1 | Jun 4, 2019 | clinicaltrials |
| NCT00595088 | Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer | completed | Phase 2 | 47 | Anchiano Therapeutics Israel Ltd.INDUSTRY | 2 | Apr 30, 2019 | clinicaltrials |
| NCT01938573 | Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer | completed | Phase 1 / Phase 2 | 21 | University of WashingtonOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT01687244 | Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer | completed | Phase 2 | 40 | FKD Therapies OyINDUSTRY | 0 | Jul 24, 2017 | clinicaltrials |
| NCT01599013 | JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin(JASINT1) | completed | Phase 2 | 69 | Pierre Fabre MedicamentINDUSTRY | 1 | Dec 8, 2015 | clinicaltrials |
| NCT02007005 | Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 37 | Abnoba GmbhINDUSTRY | 2 | May 6, 2015 | clinicaltrials |
| NCT00407485 | VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | completed | Phase 2 | 22 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2014 | clinicaltrials |
| NCT01939756 | Intravesical Natural Baobab Oil in the Management of BCG-induced Lower Urinary Tract Symptoms(Baobab) | completed | Phase 1 / Phase 2 | 50 | Savino M. Di StasiOTHER | 1 | Sep 11, 2013 | clinicaltrials |
| NCT00005831 | Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2013 | clinicaltrials |
| NCT00322699 | Sequential Whole Bladder Photodynamic Therapy (WBPDT) in the Management of Superficial Bladder Cancer | completed | Phase 1 / Phase 2 | 22 | North Florida/South Georgia Veterans Health SystemOTHER | 1 | Oct 26, 2012 | clinicaltrials |
| NCT00330707 | Combined Use of BCG and Interferon Alpha in Bladder Cancer | completed | Phase 2 / Phase 3 | 140 | National University Hospital, SingaporeOTHER | 1 | Mar 4, 2011 | clinicaltrials |
| NCT00192049 | A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer | completed | Phase 2 | 90 | Eli Lilly and CompanyINDUSTRY | 1 | May 17, 2007 | clinicaltrials |
| NCT00191711 | Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk. | completed | Phase 2 | 43 | Eli Lilly and CompanyINDUSTRY | 1 | Jan 26, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Apr 1, 2026source: clinicaltrials